Home Drug IndexClinical Monograph

Tamsulosin Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

Therapeutic Class

Alpha-adrenergic antagonist

Subclass

Selective alpha-1A adrenergic receptor blocker

Speciality

Urology

Schedule (India)

Schedule H

Routes

Oral

Formulations

Form	Strength
Modified-release capsules/tablets	0.4 mg
Capsules (limited availability)	Unidentified

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Benign Prostatic Hyperplasia (BPH) — Lower Urinary Tract Symptoms (LUTS)

Parameter	Details
Starting dose	0.4 mg orally once daily, taken 30 minutes after the same meal each day
Titration	Not routinely required; may increase to 0.8 mg once daily after 2–4 weeks if response inadequate and drug well tolerated
Usual maintenance dose	0.4 mg once daily
Maximum dose	0.8 mg once daily

Clinical Notes:

Do not crush, chew, or open modified-release capsules
Response typically observed within 1–2 weeks of initiation
Evaluate for orthostatic hypotension risk at initiation, particularly in elderly
Not effective for prostatic obstruction requiring surgical intervention

Secondary Indications — Adults (Off-label, if any)

Indication	Dose	Duration	Notes
Distal ureteric stones — Medical Expulsion Therapy (MET) — OFF-LABEL	0.4 mg once daily	Up to 4–6 weeks or until stone passage	Specialist only (Urology). Most effective for stones 5–10 mm in distal ureter. Evidence: Multiple meta-analyses support efficacy; standard practice in Indian urology.
Chronic prostatitis / Chronic pelvic pain syndrome (CP/CPPS) — OFF-LABEL	0.4 mg once daily	6–12 weeks trial	Specialist only. Evidence: Limited RCT data; used in Indian urological practice for symptom relief.

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India)

Not applicable — Tamsulosin is not approved for routine paediatric use in India.

Secondary Indications — Paediatrics (Off-label, if any)

Indication	Age	Dose	Duration	Notes
Posterior urethral valve (PUV) — residual bladder outlet obstruction — OFF-LABEL	≥2 years	0.2 mg once daily	As directed by specialist	Specialist only (Paediatric urology/nephrology). Adjust based on weight and clinical response. Evidence: Limited case series; select Indian tertiary centre practice.
Neurogenic bladder / Dysfunctional voiding — OFF-LABEL	≥2 years	0.2 mg once daily	As directed by specialist	Specialist only. Monitor closely for hypotension and dizziness. Evidence: Limited; based on specialist practice.

Not recommended below 2 years of age except under close paediatric urology or nephrology supervision.

Safety Monitoring:

Baseline and periodic blood pressure (supine and standing)
Monitor for dizziness, syncope, excessive fatigue
Assess clinical response and voiding parameters

Renal Adjustments

Renal Function	Recommendation
Mild to moderate impairment (CrCl ≥30 mL/min)	No dose adjustment required
Severe impairment (CrCl <30 mL/min)	Use with caution; limited pharmacokinetic data
CrCl <10 mL/min	Avoid 0.8 mg dose; use standard 0.4 mg with close monitoring
Haemodialysis	No specific data; not significantly dialysed; use with caution

Hepatic adjustment

Contraindications

Known hypersensitivity to tamsulosin hydrochloride or any excipient
History of symptomatic orthostatic hypotension
Severe hepatic impairment (Child-Pugh C)
Concurrent use with potent CYP3A4 inhibitors (ketoconazole, itraconazole) in patients who are CYP2D6 poor metabolizers

Cautions

Elderly patients — increased susceptibility to orthostatic hypotension and falls
Volume depletion or concurrent diuretic therapy
Intraoperative Floppy Iris Syndrome (IFIS) — may complicate cataract surgery; document drug history and inform ophthalmologist
Patients on antihypertensive medications — additive hypotensive effects
Priapism — rare but requires immediate attention
Severe renal impairment (CrCl <10 mL/min) — limited data
Patients with planned ophthalmic surgery — assess timing of drug discontinuation

Pregnancy

Parameter	Details
Applicability	Not applicable — drug indicated only for males
Safety in pregnancy	Not studied; no obstetric indication
Preferred alternatives	Not applicable
Monitoring	Not applicable

Lactation

Parameter	Details
Applicability	Not applicable — drug indicated only for males
Compatibility with breastfeeding	Not applicable
Milk levels	No data available
Infant monitoring	Not applicable

Elderly'

Parameter	Recommendation
Starting dose	0.4 mg once daily
Titration	Slower titration if escalating to 0.8 mg; reassess tolerance after 4 weeks
Extra risks	Higher susceptibility to orthostatic hypotension, dizziness, syncope, and falls. Advise slow positional changes. Maintain adequate hydration. Consider fall risk assessment in frail elderly.

Major drug interactions

Interacting Drug	Mechanism / Effect	Recommendation
Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin)	Marked increase in tamsulosin plasma concentration	Avoid concurrent use; if unavoidable, close monitoring and consider dose reduction
Strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion)	Increased tamsulosin exposure (~30%)	Use with caution; monitor for hypotensive symptoms
PDE-5 inhibitors (sildenafil, tadalafil, vardenafil)	Additive hypotensive effect	Space doses by at least 4–6 hours; monitor blood pressure; counsel patient
Other alpha-1 blockers (prazosin, doxazosin, terazosin, alfuzosin)	Synergistic hypotension	Avoid concurrent use

Moderate drug interactions

Interacting Drug	Effect	Recommendation
Antihypertensives (ACE inhibitors, ARBs, beta-blockers, CCBs, diuretics)	Additive blood pressure lowering	Monitor BP; adjust antihypertensive doses if symptomatic hypotension occurs
Cimetidine	Modest increase in tamsulosin levels (~26%)	Clinical monitoring; routine dose adjustment usually not required
Warfarin	Isolated case reports of altered INR	Monitor INR if initiating or stopping tamsulosin; no routine adjustment
Furosemide / Thiazides	Volume depletion may worsen orthostatic hypotension	Ensure adequate hydration; monitor postural symptoms
NSAIDs	May reduce efficacy of antihypertensive effect; potential for worsening postural symptoms in some patients	Monitor clinical response

Common Adverse effects

Dizziness
Abnormal ejaculation (retrograde ejaculation, reduced ejaculate volume)
Headache
Rhinitis / nasal congestion
Asthenia / fatigue
Orthostatic hypotension (less common than non-selective alpha-blockers)

Serious Adverse effects

Adverse Effect	Clinical Notes
Severe hypotension / syncope	Requires immediate discontinuation; evaluate for contributing factors (dehydration, concurrent medications)
Intraoperative Floppy Iris Syndrome (IFIS)	Risk persists even after drug discontinuation; inform ophthalmologist prior to cataract surgery
Priapism	Rare; requires urgent discontinuation and immediate urological referral
Angioedema / severe hypersensitivity	Rare; discontinue immediately and manage appropriately

Monitoring requirements

Baseline:

Blood pressure (supine and standing)
IPSS (International Prostate Symptom Score) for objective symptom assessment
Renal and hepatic function if clinically indicated
Document any planned ophthalmic surgery

After initiation/dose change:

Monitor for orthostatic symptoms (dizziness, light-headedness) during first 1–2 weeks
Blood pressure check if on concurrent antihypertensives
Assess symptom improvement (IPSS, uroflowmetry if available) at 4–6 weeks

Long-term:

Periodic IPSS reassessment every 6–12 months
Blood pressure monitoring during routine follow-up
Document tamsulosin use prominently if ophthalmic surgery planned

Brands in India

Brand Name	Manufacturer
Urimax	Cipla
Contiflo	Sun Pharma
Veltam	Aristo
Flotral	Intas
Tamlocept	Lupin
Dynapres	Micro Labs

Common Fixed-Dose Combinations (FDCs):

Tamsulosin 0.4 mg + Dutasteride 0.5 mg (e.g., Urimax D, Veltam Plus, Dutas T)
Tamsulosin 0.4 mg + Finasteride 5 mg

Price range (INR)

Formulation	Approximate Price
Tamsulosin 0.4 mg MR capsule (per unit)	₹7–20
Tamsulosin + Dutasteride FDC (per capsule)	₹10–25

Regulatory status: Tamsulosin is included in NLEM 2022; pricing under NPPA control for scheduled formulations.

Clinical pearls

Timing consistency is important — Administer after the same meal each day to reduce pharmacokinetic variability and minimise hypotension risk.
IFIS alert is mandatory — Always document tamsulosin use in medical records and ensure patient informs ophthalmologist before any cataract or intraocular surgery. IFIS risk persists even months after stopping the drug.
Reserve FDCs appropriately — Tamsulosin + Dutasteride combination should be considered only when prostate volume exceeds 30–40 mL with moderate-to-severe LUTS; monotherapy suffices for smaller glands.
Ejaculatory dysfunction counselling — Discuss ejaculatory changes (retrograde ejaculation) upfront, especially with younger sexually active patients.
Not a treatment for all LUTS — Tamsulosin is ineffective for overactive bladder, isolated nocturia, or bladder storage symptoms; confirm outlet obstruction before initiating.
Postural precaution in elderly — Counsel patients to rise slowly from sitting or supine position, particularly in the first few weeks of therapy.

Version

RxIndia v1.0 — 03 Apr 2025

Reference

CDSCO product insert (Urimax, Cipla)
Indian Pharmacopoeia / NFI 2021
NLEM 2022
API Textbook of Medicine
Indian Urological Association practice guidelines
AIIMS Delhi Hospital Formulary

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...